Ignite Creation Date:
2024-05-06 @ 8:06 PM
Last Modification Date:
2024-10-26 @ 3:20 PM
Study NCT ID:
NCT06250283
Status:
RECRUITING
Last Update Posted:
2024-03-25
First Post:
2024-01-18
Brief Title:
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women
Sponsor:
University of Delaware
Organization:
University of Delaware
Study Overview
Official Title:
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine whether daily supplementation of resveratrol would improve bone health in postmenopausal women
Detailed Description:
34 women will be randomly assigned to two groups 1 the placebo group and 2 the resveratrol group The resveratrol group will receive 500 mg resveratrol daily for 24 weeks and placebo group will receive placebo pills Both groups will receive 500 mg calcium plus 400 IU vitamin D daily
Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks
Blood and urinary biomarkers of bone metabolism will be assessed at baseline and after 12 and 24 weeks intervention Bone mineral density will be assessed using dual-energy X-ray absorptiometry at baseline and after 24 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U54GM104941 | NIH | None | httpsreporternihgovquickSearchU54GM104941 |